Substance / Medication

Brincidofovir

Overview

Active Ingredient
brincidofovir
RxNorm CUI
2599518
Labeler: Emergent BioDefense Operations Lansing LLCUpdated: 2025-07-23T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

5.1 [see Warnings and Precautions ()] An increased incidence of mortality was seen in TEMBEXA-treated subjects compared to placebo-treated subjects in a 24-week clinical trial when TEMBEXA was evaluated in another disease.

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
A quantitative LC-MS/MS method for the determination of tissue brincidofovir and cidofovir diphosphate in a MuPyV-infected mouse model.
Guzman Bryan B, Schauer Amanda P, Dunn John A et al. · Biomed Chromatogr · 2021
PMID: 33398885Observational
Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients.
Lee Yeon Joo, Neofytos Dionysios, Kim Seong Jin et al. · Transpl Infect Dis · 2018
PMID: 30120866ObservationalFull text (PMC)
Disseminated Mpox infection, a rare case of an immunocompromised patient treated with tecovirimat and brincidofovir.
Klein Paytra A, Parisi Rose, Ramani Ananthakrishnan · JAAD Case Rep · 2025
PMID: 40337302Case ReportFull text (PMC)
The successful treatment of mpox with brincidofovir in renal transplant recipients-a report of 2 cases.
Alameer Reem M, Yamani Amani, Al-Saud Abdulrahman et al. · Int J Infect Dis · 2024
PMID: 38521447Case Report
Brincidofovir for disease progression due to suspected tecovirimat resistance in association with advanced HIV.
Harrison Iris, DeSear Kathryn, Santevecchi Barbara A et al. · Int J STD AIDS · 2024
PMID: 38502040Case Report
Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection.
Chan Shuk Ying, Prockop Susan E, Boulad Farid et al. · Infect Chemother · 2021
PMID: 32869551Case ReportFull text (PMC)
Initial Experience Treating HPV-Related Laryngeal Diseases with Oral Brincidofovir: A Pilot Study.
Richardson Brent E · Ann Otol Rhinol Laryngol · 2021
PMID: 33834883Case Report
Failure of antiviral therapy with brincidofovir in non-HIV progressive multifocal leukoencephalopathy.
Talarmin Jean-Philippe, Rezig Schéhérazade, Tran-Minoui Adissa et al. · Acta Neurol Belg · 2020
PMID: 32072465Case Report
Brincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients: A case series.
Londeree Jackson, Winterberg Pamela D, Garro Rouba et al. · Pediatr Transplant · 2020
PMID: 32558134Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Brincidofovir (substance)
SNOMED CT
1162582005
UMLS CUI
C3886763
RxNorm CUI
2599518
Labeler
Emergent BioDefense Operations Lansing LLC

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.